Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Hospice Informal Caregivers
Interventions: Problem Solving Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Syncope, Vasovagal
Interventions: CPC - Capsaicin, Phenylephrine, Caffeine, Tilt Table Test, Placebo; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Carboplatin, Nab-paclitaxel, GM-CSF, Trastuzumab, Bevacizumab; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Conditions: Pediatric Heart Failure
Interventions: LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Asthma
Interventions: Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more

Conditions: Healthy
Interventions: LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteer
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
Interventions: ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham; Drug · Other
Lead sponsor: ONL Therapeutics; Industry
Eligibility: 55 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 56
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 50 more

Conditions: Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8, Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Atezolizumab, Bevacizumab, Cobimetinib, Nab-paclitaxel, Paclitaxel, Vemurafenib; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions: adrulipase; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Orlando, Florida • Northfield, Illinois • Las Vegas, Nevada

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor
Interventions: SMP3124LP; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Cystic Fibrosis
Interventions: VX-581; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acute Lymphoblastic Leukemia
Interventions: 6-Mercaptopurine; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 4 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy
Interventions: PF-04308515, Placebo, PF-04308515 Tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Plantar Fasciitis
Interventions: Topical oil application; Other
Lead sponsor: Center for Biomedical Research, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Sunscreening Agents
Interventions: Sunscreen Sport Lotion (BAY987516), Untreated Skin; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Amblyopia
Interventions: levodopa/carbidopa, patching; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 8 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 16
States / cities: Anaheim, California • Cerritos, California • Chula Vista, California + 13 more

Conditions: Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics,, Tumour Response.
Interventions: Intermittent dosing of AZD5363; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Alopecia, Alopecia, Androgenetic, Baldness
Interventions: bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Test Formulation, Ocrelizumab Reference Formulation; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Carlsbad, California • Fort Collins, Colorado • Maitland, Florida + 6 more

Search by objective public record fields.

Hospice Problem Solving Intervention

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Neoadjuvant Treatment of Breast Cancer

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

A Study of LY3502970 in Healthy Participants

A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

SMP-3124LP in Adults With Advanced Solid Tumors

A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

Multiple Dose Escalation Trial Of PF-04308515 In Healthy Volunteers

Topical Phytoterpenes for Plantar Fasciitis

Human Phototoxicity Test

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)